Endomagnetics appoints Aurora BioScience as ANZ distributor

UK healthcare company Endomagnetics has reached an agreement with Aurora BioScience as its exclusive distributor for Australia and New Zealand. The appointment will provide breast cancer patients in the region with access to technology that optimally locates lymph nodes as part of the cancer staging procedure in sentinel lymph node biopsy (SLNB).

The current standard of care for SLNB requires a radioactive isotope injection, which has limited availability in Australia and New Zealand. The Endomagnetics SentiMag tracer system is said to increase the availability of the standard of care and improve workflow, putting the surgeon in control of tracer injection. The system has been used in 10 clinical studies and trials with over 1500 patients across 12 European countries since 2012.

“We are delighted to be working with the team at Aurora as this appointment significantly strengthens our distribution in this key geographical market,” said Endomagnetics Director of Sales and Business Development Mathew Stephens. “The interest from Australian and New Zealand surgeons has been huge and we are looking forward to developments in the coming months.”

Aurora Bioscience will be exclusively responsible for the sales, marketing and distribution of the SentiMag system in the Australian and New Zealand markets. The company is a specialist distributor of high-tech medical devices across fields including oncology, blood technology, respiratory medicine and neurology.

“The Endomagnetics technology is a perfect fit with our advanced, innovative range of medical devices, and the technology will significantly improve patient experience by extending availability of the SLNB technique,” said Aurora BioScience Managing Director Darren Banks.